P
10.73
0.01 (0.09%)
| Penutupan Terdahulu | 10.72 |
| Buka | 10.80 |
| Jumlah Dagangan | 460,442 |
| Purata Dagangan (3B) | 1,306,273 |
| Modal Pasaran | 952,870,656 |
| Harga / Jualan (P/S) | 11.67 |
| Harga / Buku (P/B) | 4.95 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| Margin Keuntungan | -98.10% |
| Margin Operasi (TTM) | -85.88% |
| EPS Cair (TTM) | -1.29 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 5.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 21.81% |
| Nisbah Semasa (MRQ) | 6.91 |
| Aliran Tunai Operasi (OCF TTM) | -42.70 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -23.09 M |
| Pulangan Atas Aset (ROA TTM) | -17.90% |
| Pulangan Atas Ekuiti (ROE TTM) | -51.25% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Menaik | Bercampur |
| Diagnostics & Research (Global) | Menaik | Bercampur | |
| Stok | Personalis, Inc. | Menaik | Menaik |
AISkor Stockmoo
0.3
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.30 |
|
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 31.49% |
| % Dimiliki oleh Institusi | 46.11% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Merck & Co., Inc. | 30 Sep 2025 | 14,044,943 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 13.00 (HC Wainwright & Co., 21.16%) | Beli |
| Median | 12.00 (11.84%) | |
| Rendah | 10.00 (Needham, -6.80%) | Beli |
| Purata | 11.60 (8.11%) | |
| Jumlah | 4 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 8.62 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Morgan Stanley | 02 Dec 2025 | 11.00 (2.52%) | Pegang | 10.10 |
| 11 Nov 2025 | 9.00 (-16.12%) | Pegang | 8.44 | |
| BTIG | 11 Nov 2025 | 12.00 (11.84%) | Beli | 8.44 |
| 22 Oct 2025 | 11.00 (2.52%) | Beli | 8.93 | |
| Guggenheim | 11 Nov 2025 | 12.00 (11.84%) | Beli | 8.44 |
| HC Wainwright & Co. | 11 Nov 2025 | 13.00 (21.16%) | Beli | 8.44 |
| 06 Nov 2025 | 10.00 (-6.80%) | Beli | 7.19 | |
| Needham | 05 Nov 2025 | 10.00 (-6.80%) | Beli | 7.66 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| TACHIBANA AARON | - | 11.21 | -103,668 | -1,162,118 |
| Jumlah Keseluruhan Kuantiti Bersih | -103,668 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -1,162,118 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 11.21 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| TACHIBANA AARON | Pegawai | 25 Nov 2025 | Jual automatik (-) | 103,668 | 11.21 | 1,162,118 |
| TACHIBANA AARON | Pegawai | 25 Nov 2025 | Pelaksanaan pilihan | 103,668 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 18 Nov 2025 | Pengumuman | Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference |
| 10 Nov 2025 | Pengumuman | Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer |
| 04 Nov 2025 | Pengumuman | Personalis Reports Third Quarter 2025 Financial Results |
| 21 Oct 2025 | Pengumuman | Personalis to Announce Third Quarter 2025 Financial Results |
| 16 Oct 2025 | Pengumuman | Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing |
| 15 Sep 2025 | Pengumuman | Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 10 Sep 2025 | Pengumuman | CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |